Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Prevalence and imaging detection of cardiac sarcoidosis in a southern european population: insights from long-term follow-up
Session:
Prémio Melhor Comunicação Oral
Speaker:
Mariana Isabel Cavaco Salvador
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.3 Myocardial Disease – Diagnostic Methods
Session Type:
Sessão de Prémios
FP Number:
---
Authors:
Mariana Salvador; Pedro Miguel Ventura; João Borges-Rosa; Rodolfo Silva; Lino Gonçalves; Gracinda Costa; Maria João Vidigal Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Background:</strong> The use of [18F]FDG-Positron Emission Tomography (PET) has become a key non-invasive tool for diagnosing and monitoring sarcoidosis. Although cardiac involvement is often cited at 5% with known geographic variation, our previous study found a higher prevalence of probable cardiac sarcoidosis (CS) (10%), with over half of these patients lacking cardiac symptoms.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Purpose:</strong> Our aim is to characterize patients with suspected CS in a southern European population over an extended follow-up period.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> We reviewed all [18F]FDG-PET reports of patients assessed for suspected sarcoidosis between January 2009 and February 2025. From this cohort, we selected patients with biopsy-confirmed sarcoidosis and applied the Heart Rhythm Society (HRS) criteria to diagnose probable CS. We gathered detailed information on clinical profiles and imaging assessments.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results:</strong> We analysed 960 [18F]FDG-PET scans; after removing duplicates, 314 patients had a histologically confirmed diagnosis of extracardiac sarcoidosis, among whom 27 (8.6%) were further classified as having probable CS (40.7% females, mean age 58.8±13.2 years) according to HRS: histological diagnosis of extracardiac sarcoidosis and uptake on [18F]FDG-PET in a pattern consistent with CS (n=15), or late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) in a pattern consistent with CS (n=11), or unexplained reduced left ventricular ejection fraction <40% (n=1). Extracardiac sarcoidosis was confirmed by lymph node (n=13), lung (n=12), bone marrow (n=1) or skin (n=1) biopsy; only one patient had an endomyocardial biopsy, which was negative. There were no cases of isolated cardiac sarcoidosis; all patients had extracardiac involvement, most commonly lungs (n=24) and lymph nodes (n=20), followed by skin (n=6), central nervous system (n=6), bone marrow (n=4), eyes (n=3), liver (n=2), spleen (n=2), kidneys (n=2), and adrenal glands (n=1). Most patients were asymptomatic (59.3%) and the majority (85.2%) had been on immunosuppressive therapy for at least one year: 22 (81.5%) received corticosteroids, often combined with methotrexate (n=9), azathioprine (n=2), or adalimumab (n=1) and one received methotrexate alone.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Conclusions:</strong> In this southern European cohort with extracardiac sarcoidosis, probable cardiac involvement occurred in 8.3% of patients, mostly asymptomatic. [18F]FDG-PET detected most cases, while CMR-LGE revealed additional PET-negative disease, highlighting the value of multimodality imaging.</span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site